GlassScriptPhysician profile
Abdullah Al-Arfaj
NPI 1780384875
$7,500.91
in general payments reported to CMS, 2019-2025
11 companies · $4,256 in 2025
The $4,256 reported for 2025 was more than what 79% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,930 · 2024: $316 · 2025: $4,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,721 · Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,721.03 |
| Food and Beverage | $779.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart USA INC | $2,239.47 | 2025 | |
| Medical Device Business Services, INC. | $1,909.93 | 2023 | Symphony |
| Alphatec Spine, INC | $1,207.64 | 2023-2025 | Other - Miscellaneous |
| Spineology INC. | $1,067.66 | 2025 | Optimesh Expandable Interbody Fusion System |
| Synthes Gmbh | $606.81 | 2023 | |
| Nevro Corp. | $163.85 | 2024 | Senza |
| Depuy Synthes Sales INC. | $140.27 | 2025 | |
| Medtronic, INC. | $91.83 | 2024 | Intellis Adaptivestim |
| Si-Bone, INC. | $39.86 | 2025 | |
| Impactortho, INC. | $19.59 | 2024 | |
| Theragen, INC. | $14.00 | 2025 | Actastim-S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Al-Arfaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.